H E Lebovitz

Summary

Publications

  1. ncbi request reprint Type 2 diabetes: an overview
    H E Lebovitz
    SUNY Downstate Medical Center, 450 Clarkson Ave, Box 1205, Brooklyn, NY 11203, USA
    Clin Chem 45:1339-45. 1999
  2. doi request reprint Metabolic surgery for type 2 diabetes: appraisal of clinical evidence and review of randomized controlled clinical trials comparing surgery with medical therapy
    Harold E Lebovitz
    State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Brooklyn, NY, 11203, USA
    Curr Atheroscler Rep 15:376. 2013
  3. doi request reprint Autoimmune polyglandular syndromes: interplay between the immune and the endocrine systems leading to a diverse set of clinical diseases and new insights into immune regulation
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
    Diabetes Technol Ther 15:S2-21-S2-28. 2013
  4. pmc Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm
    H E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, NY, USA
    Diabet Med 30:687-93. 2013
  5. pmc Metabolic surgery for type 2 diabetes with BMI <35 kg/m(2) : an endocrinologist's perspective
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, NY, USA
    Obes Surg 23:800-8. 2013
  6. doi request reprint Science, clinical outcomes and the popularization of diabetes surgery
    Harold E Lebovitz
    State University of New York Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
    Curr Opin Endocrinol Diabetes Obes 19:359-66. 2012
  7. doi request reprint Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease
    Harold E Lebovitz
    Department of Medicine, Division of Endocrinology, State University of New York Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
    Diabetes Technol Ther 14:S43-50. 2012
  8. doi request reprint Type 2 diabetes mellitus--current therapies and the emergence of surgical options
    Harold E Lebovitz
    State University of New York Health Science Center at Brooklyn, Department of Medicine, Brooklyn, New York, NY 11203, USA
    Nat Rev Endocrinol 7:408-19. 2011
  9. doi request reprint Adjunct therapy for type 1 diabetes mellitus
    Harold E Lebovitz
    Department of Medicine, Division of Endocrinology, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, New York, NY 11203, USA
    Nat Rev Endocrinol 6:326-34. 2010
  10. doi request reprint New treatments of diabetes: the beta-amylin agonists
    H E Lebovitz
    Health Science Center at Brooklyn, Endocrinology and Metabolism Diabetes, State University of New York, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Ann Endocrinol (Paris) 69:147-50. 2008

Detail Information

Publications17

  1. ncbi request reprint Type 2 diabetes: an overview
    H E Lebovitz
    SUNY Downstate Medical Center, 450 Clarkson Ave, Box 1205, Brooklyn, NY 11203, USA
    Clin Chem 45:1339-45. 1999
    ..Long-term glycemic control in type 2 diabetes requires progressive, stepwise, combination treatment with oral agents and eventually combination treatment with oral agents and insulin...
  2. doi request reprint Metabolic surgery for type 2 diabetes: appraisal of clinical evidence and review of randomized controlled clinical trials comparing surgery with medical therapy
    Harold E Lebovitz
    State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Brooklyn, NY, 11203, USA
    Curr Atheroscler Rep 15:376. 2013
    ..They show that future trials will have to be much larger and last for at least 5-10 years. ..
  3. doi request reprint Autoimmune polyglandular syndromes: interplay between the immune and the endocrine systems leading to a diverse set of clinical diseases and new insights into immune regulation
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
    Diabetes Technol Ther 15:S2-21-S2-28. 2013
    ..The APSs epitomize the synergies that the merger of clinical and basic science can achieve. This is the environment that George Eisenbarth was able to create at the Barbara Davis Center for Diabetes...
  4. pmc Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm
    H E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, NY, USA
    Diabet Med 30:687-93. 2013
    ..A preliminary analysis of data from patients who had completed 6 months of treatment indicated that the glycaemic response to the electrical stimulation was inversely related to the baseline fasting plasma triglyceride level...
  5. pmc Metabolic surgery for type 2 diabetes with BMI <35 kg/m(2) : an endocrinologist's perspective
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, NY, USA
    Obes Surg 23:800-8. 2013
    ..Current data do not justify bariatric surgery as primary therapy for T2DM with BMI <35 kg/m(2)...
  6. doi request reprint Science, clinical outcomes and the popularization of diabetes surgery
    Harold E Lebovitz
    State University of New York Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
    Curr Opin Endocrinol Diabetes Obes 19:359-66. 2012
    ..Bariatric surgery is an important option for the treatment of severe (type III) obesity. Its role in the management of type 2 diabetes in overweight and obese patients needs to be defined...
  7. doi request reprint Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease
    Harold E Lebovitz
    Department of Medicine, Division of Endocrinology, State University of New York Health Science Center at Brooklyn, Brooklyn, New York 11203, USA
    Diabetes Technol Ther 14:S43-50. 2012
    ..Whether these will decrease cardiovascular events is currently under investigation...
  8. doi request reprint Type 2 diabetes mellitus--current therapies and the emergence of surgical options
    Harold E Lebovitz
    State University of New York Health Science Center at Brooklyn, Department of Medicine, Brooklyn, New York, NY 11203, USA
    Nat Rev Endocrinol 7:408-19. 2011
    ..Interventional surgery might, therefore, be considered a reasonable therapeutic alternative for overweight and obese (BMI <35 kg/m²) patients with T2DM who do not respond to medical therapy...
  9. doi request reprint Adjunct therapy for type 1 diabetes mellitus
    Harold E Lebovitz
    Department of Medicine, Division of Endocrinology, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, New York, NY 11203, USA
    Nat Rev Endocrinol 6:326-34. 2010
    ....
  10. doi request reprint New treatments of diabetes: the beta-amylin agonists
    H E Lebovitz
    Health Science Center at Brooklyn, Endocrinology and Metabolism Diabetes, State University of New York, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Ann Endocrinol (Paris) 69:147-50. 2008
  11. ncbi request reprint Oral therapies for diabetic hyperglycemia
    H E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York, USA
    Endocrinol Metab Clin North Am 30:909-33. 2001
    ..In choosing combinations of oral antihyperglycemic agents, their effects on the components treatment of type 2 diabetic patients. These classes improve glucose considered, as must the specific effects of the agents on glucose metabolism...
  12. ncbi request reprint Rosiglitazone monotherapy is effective in patients with type 2 diabetes
    H E Lebovitz
    Department of Medicine, State University of New York, Brooklyn, New York 11203, USA
    J Clin Endocrinol Metab 86:280-8. 2001
    ..In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions...
  13. ncbi request reprint Insulin resistance and its treatment by thiazolidinediones
    H E Lebovitz
    State University of New York, Health Science Center at Brooklyn, 11203, USA
    Recent Prog Horm Res 56:265-94. 2001
    ....
  14. ncbi request reprint Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men
    M A Banerji
    Department of Medicine, State University of New York Health Science Center, Brooklyn 11203, USA
    J Clin Endocrinol Metab 84:137-44. 1999
    ..Increased visceral fat is related to dyslipidemia and increased frequency of insulin resistance and may account for the increased prevalence of diabetes mellitus and cardiovascular disease in Asian Indians...
  15. ncbi request reprint Insulin resistance: definition and consequences
    H E Lebovitz
    State University of New York Health Science Center at Brooklyn, USA
    Exp Clin Endocrinol Diabetes 109:S135-48. 2001
    ..In this context, we need to consider whether insulin resistance should be defined as a disease entity which needs to be diagnosed and treated with specific drugs to improve insulin action...
  16. ncbi request reprint Diagnosis, classification, and pathogenesis of diabetes mellitus
    H E Lebovitz
    State University of New York Health Science Center at Brooklyn, USA
    J Clin Psychiatry 62:5-9; discussion 40-1. 2001
    ..A monitoring system should be in place in patients started on treatment with these agents to detect metabolic abnormalities as they are evolving so that adequate and timely treatment can be initiated...
  17. ncbi request reprint Effect of the postprandial state on nontraditional risk factors
    H E Lebovitz
    State University of New York Health Sciences Center, Brooklyn, New York 11203, USA
    Am J Cardiol 88:20H-5H. 2001
    ....